Thiazolidinediones(TZDs) is an antidiabetic drug class which is used to decrease insulin resistance by their ability to improve insulin sensitivity. TZDs ability to control glucose is dependent on the insulin production of the pancreas, and works by binding to plasma proteins and is metabolized by the liver.^2 This class of drugs has been slow to show improvement in the control of glucose; which can take up to three to four months.^2 There are two TZDs that are currently used, pioglitazone and rosiglitazone. While both of these TZDs have been studied on their adverse effects, pioglitazone has been more commonly associated with bladder cancer.
A retrospective cohort study using a nested-case control analysis was conducted between January 1988